Ann: Appointment of VP Clinical Operations & Data Management, page-16

Targeting CDH17 holds great promise and there is mounting pre-clinical evidence supporting that.

For example, I found this article published in Frontiers of Immunology last week, "Recent Progress and Future Prespectives of Immunotherapy in Advanced Gastric Cancer", which links (61) to the article in Nature:



Reference (60) refers to a study published in January this year, "Antitumor responses in gastric cancer by targeting B7H3 via chimeric antigen receptor T cells", which sheds some light into the target B7H3:



[...]



[...]



[..]



[...]



Coming back to the article quoted at the beginning and one of the potential issues with the above:



That's where CHM's approach could help.

According to the underlying patent:


[...]


https://patents.google.com/patent/WO2019210155A1/en


Also mentioned in Nature (see ASX announcement):




This T cell derived autologous therapy will eventually also lead us to our NK cell derived allogeneic therapy:



And the above only covers a small part of what CHM has to offer... for a MC of less than A$45 million.